Actively Recruiting
Observing Real-world Use of Nemolizumab for Moderate-to-Severe Prurigo Nodularis in Adults Over 12 Months
Led by Galderma R&D · Updated on 2026-09-09
600
Participants Needed
51
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the real-world effectiveness of nemolizumab Nemluvio4 in treating adults with moderate-to-severe Prurigo Nodularis PN. This observational study aims to measure patient and investigator-reported outcomes over approximately 12 months in routine clinical practice. The study focuses on how patients respond to nemolizumab treatment at 6 months, with ongoing assessments up to a year. Participants who have newly started nemolizumab as determined by their physicians will be observed during their usual care visits. No extra visits, procedures, or lab tests beyond routine care are required. A sub-study in Germany and the UK involves daily patient-reported ratings of itch severity and sleep disturbance for two weeks, collected remotely without clinic visits. During the study, participants will undergo routine evaluations by their doctors, including the Investigator Global Assessment of chronic prurigo stage and questionnaires on itch intensity and sleep quality. These assessments occur at 6 months and continue up to 12 months. This approach allows tracking of treatment effects in real-life settings while minimizing additional burden on participants.
CONDITIONS
Brief Title
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
Research Team
G
Galderma Research and Development
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here